Hypertension
Conditions
Brief summary
The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.
Interventions
Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
OTHERCardiovascular risk factors
Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
Sponsors
Beijing Tsinghua Chang Gung Hospital
Beijing Tiantan Hospital
Ruijin Hospital
Nanfang Hospital, Southern Medical University
Southwest Hospital, China
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of hypertension * over 18 years old * ti sign the informed consent
Exclusion criteria
* with life-threatening severe disease, such as severe tumor or AIDs * pregnancy or lactating women,or plan to pregnant within half a year, * with severe mental disorders * participating in clinical trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite end point of major cardiovascular and cerebrovascular events | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | Composite end point of major cardiovascular and cerebrovascular events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| New-onset of cardiovascular events | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | New-onset of cardiovascular events |
| New-onset of stroke | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | New-onset of stroke |
| Total death | From date of enrollment until date of death from all cause, assessed up to 3 year | Total death |
| Major bleeding | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | Major bleeding |
| Atrial fibrillation | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | Atrial fibrillation |
Countries
China
Contacts
Primary ContactYue Qi, PhD
Outcome results
None listed